Control of Moderate-to-Severe Plaque Psoriasis with Efalizumab: 24-Week, Open-Label, Phase IIIb/IV Latin American Study Results

INTRODUCTION: Psoriasis is a debilitating, chronic inflammatory systemic disease affecting around 2% of the South American population. Biological therapies offer the possibility of long-term therapy with improved safety and efficacy. METHODS: We conducted a multicentre, open-label, single-arm, Phase...

Full description

Saved in:
Bibliographic Details
Main Authors: Stengel, Fernando M, Petri, Valeria, Campbell, Gladys AM, Dorantes, Gladys Leon, López, Magdalina, Galimberti, Ricardo L, Valdez, Raúl P, de Arruda, Lucia F, Guerra, Mario Amaya, Chouela, Edgardo N, Licu, Daiana
Format: Artigo
Language:Inglês
Published: Blackwell Publishing Inc 2009
Subjects:
Original Articles
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2805872/
https://ncbi.nlm.nih.gov/pubmed/20098510
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1753-5174.2009.00024.x
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items